CXCR4 and type 2 diabetes mellitus: Canagliflozin when added to subjects with Type 2 Diabetes along with metformin and/or Insulin, demonstrates a functional improvement of CD34+ Endothelial Progenitor Cell migratory function through increased CD34/CXCR4 positivity.